1354327-80-2

Upstream product

• 21193-75-9 D-galactal 
• 122350-80-5 2-((trityloxy)methyl)-3,4-dihydro-2H-pyran-3,4-diol 
• 112-44-7 undecylaldehyde 
• 1354327-76-6 C₅₂H₆₂N₂O₆S 
• 1354327-74-4 C₅₁H₆₀N₂O₄ 
• 131645-01-7 C₁₁H₂₆N₂ 
• 1354327-73-3 C₁₉H₃₂N₂O₂ 
• 1354327-71-1 C₄₀H₃₆O₅ 
• 1354327-78-8 C₅₁H₅₉N₅O₃ 

Downstream Products

• 1354327-82-4 C₆₆H₇₉N₅O₈ 

Relevant academic research and scientific papers

Alpha-galactosylceramide analogs, a preparation method thereof, and a pharmaceutical composition for treatment and prevention of diseases by abnormal immune modulation comprising the same

The present invention refers to alpha - ceramide analogs, including manufacturing method of immunomodulatory or pharmaceutical composition for treating or preventing diseases caused and relates to, more particularly NKT intracellular Th1 or selective activation reaction Th2 can be effective for treating or preventing diseases caused immunomodulatory or alpha - ceramide analogs, and manufacturing method of including a pharmaceutical composition for treating or preventing diseases caused immunomodulatory or more are disclosed. (by machine translation)

Heteroaromatic moieties in the sphingosine backbone of α- Galactosylceramides for noncovalent interactions with CD1d

A series of α-GalCer analogues containing heterocyclic and aromatic moieties in the sphingosine backbone were synthesized to improve the selectivity in the Th1/Th2 cytokine profile via noncovalent interaction with three aromatic residues at the binding pocket of CD1d. In vitro and in vivo biological evaluations revealed the treatment of α-GalCer analogue (6) induced the selective stimulation of natural killer T cells to facilitate the secretion of Th2 cytokines.